Alternations in miR-155 and miR-200 serum levels can serve as biomarkers for COVID-19 in the post-mass vaccination era
Background Mass vaccination and natural immunity reduced the severity of COVID-19 cases. SARS-CoV-2 ongoing genome variations imply the use of confirmatory serologic biomarkers besides PCR for reliable diagnosis. MicroRNA molecules are intrinsic components of the innate immune system. The expression...
Gespeichert in:
| Veröffentlicht in: | Molecular biology reports 2024-12, Vol.51 (1), p.689-689, Article 689 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 689 |
|---|---|
| container_issue | 1 |
| container_start_page | 689 |
| container_title | Molecular biology reports |
| container_volume | 51 |
| creator | Aboulela, Aliaa Taha, Mona Ghazal, Abeer Baess, Ayman Elsheredy, Amel |
| description | Background
Mass vaccination and natural immunity reduced the severity of COVID-19 cases. SARS-CoV-2 ongoing genome variations imply the use of confirmatory serologic biomarkers besides PCR for reliable diagnosis. MicroRNA molecules are intrinsic components of the innate immune system. The expression of miR155-5p and miR200c-3p was previously correlated with SARS-CoV-2 pathogenesis. This case-control study was conducted during the third peak of the COVID-19 pandemic in Egypt and aimed to calculate the accuracy of miR155-5p and miR200c-3p as biomarkers for COVID-19.
Methods and results
Thirty out of 400 COVID-19 patients at a main University hospital in Alexandria were included in the study along with 20 age-matched healthy controls. Plasma samples were collected for total and differential CBC. Relative quantitation of miR155-5p and miR200c-3p expression from WBCs was done by RT-qPCR. The expression of miR155-5p and miR200c-3p was positively correlated and was significantly downregulated in COVID-19 patients compared to the healthy control group (p ˂ 0.005). Both miR155-5p and miR200c-3p were of 76% and 74% accuracy as diagnostic biomarkers of COVID-19, respectively. Regarding the differentiation between mild and moderate cases, their accuracy was 80% and 70%, respectively.
Conclusions
miR155-5p and miR200c-3p expression can be used to confirm the diagnosis of COVID-19 and discriminate between mild and moderate cases, with a moderate degree of accuracy. |
| doi_str_mv | 10.1007/s11033-024-09630-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3060747421</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3060747421</sourcerecordid><originalsourceid>FETCH-LOGICAL-c256t-192dfc41d8e56d24113e1cafa55d89fd43ca2a24c59d56c8c81417a5397d74333</originalsourceid><addsrcrecordid>eNp9kU1LHTEUhoO06PXjD3QhgW66SZuTz5mlXNsqCIKo2xCTTDt2Pq45Mxf89811bAsuukpInvMcznkJ-QD8M3BuvyAAl5JxoRivjeRM7JEVaCuZqm31jqy45MBUpeGAHCI-cs4VWL1PDmRla2M0rMj2rJtSHvzUjgPSdqB9e8NAa-qH-HIXnFNMee5pl7apQxr8sHvYJuqRPrRj7_OvlJE2Y6br6_vLcwb1TjT9THQz4sR6j0i3PoR2aUNT9sfkfeM7TCev5xG5-_b1dn3Brq6_X67PrlgQ2kzFJGITFMQqaROFApAJgm-81rGqm6hk8MILFXQdtQlVqKBM6LWsbbRKSnlEPi3eTR6f5oST61sMqev8kMYZneSGW2WVgIJ-fIM-jnPZTLdQBTPSFEosVMgjYk6N2-S2rODZAXe7VNySiiupuJdUnChFp6_q-aFP8W_JnxgKIBcAy9fwI-V_vf-j_Q2kZ5Tv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3060074636</pqid></control><display><type>article</type><title>Alternations in miR-155 and miR-200 serum levels can serve as biomarkers for COVID-19 in the post-mass vaccination era</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Aboulela, Aliaa ; Taha, Mona ; Ghazal, Abeer ; Baess, Ayman ; Elsheredy, Amel</creator><creatorcontrib>Aboulela, Aliaa ; Taha, Mona ; Ghazal, Abeer ; Baess, Ayman ; Elsheredy, Amel</creatorcontrib><description>Background
Mass vaccination and natural immunity reduced the severity of COVID-19 cases. SARS-CoV-2 ongoing genome variations imply the use of confirmatory serologic biomarkers besides PCR for reliable diagnosis. MicroRNA molecules are intrinsic components of the innate immune system. The expression of miR155-5p and miR200c-3p was previously correlated with SARS-CoV-2 pathogenesis. This case-control study was conducted during the third peak of the COVID-19 pandemic in Egypt and aimed to calculate the accuracy of miR155-5p and miR200c-3p as biomarkers for COVID-19.
Methods and results
Thirty out of 400 COVID-19 patients at a main University hospital in Alexandria were included in the study along with 20 age-matched healthy controls. Plasma samples were collected for total and differential CBC. Relative quantitation of miR155-5p and miR200c-3p expression from WBCs was done by RT-qPCR. The expression of miR155-5p and miR200c-3p was positively correlated and was significantly downregulated in COVID-19 patients compared to the healthy control group (p ˂ 0.005). Both miR155-5p and miR200c-3p were of 76% and 74% accuracy as diagnostic biomarkers of COVID-19, respectively. Regarding the differentiation between mild and moderate cases, their accuracy was 80% and 70%, respectively.
Conclusions
miR155-5p and miR200c-3p expression can be used to confirm the diagnosis of COVID-19 and discriminate between mild and moderate cases, with a moderate degree of accuracy.</description><identifier>ISSN: 0301-4851</identifier><identifier>EISSN: 1573-4978</identifier><identifier>DOI: 10.1007/s11033-024-09630-2</identifier><identifier>PMID: 38796651</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Accuracy ; Adult ; Animal Anatomy ; Animal Biochemistry ; Biomarkers ; Biomarkers - blood ; Biomedical and Life Sciences ; Case-Control Studies ; COVID-19 ; COVID-19 - blood ; COVID-19 - diagnosis ; COVID-19 vaccines ; Diagnosis ; Egypt - epidemiology ; Female ; Genomes ; Histology ; Humans ; Immune system ; Innate immunity ; Life Sciences ; Male ; MicroRNAs - blood ; MicroRNAs - genetics ; Middle Aged ; miRNA ; Morphology ; Original Article ; SARS-CoV-2 - genetics ; Serum levels ; Severe acute respiratory syndrome coronavirus 2 ; Vaccination</subject><ispartof>Molecular biology reports, 2024-12, Vol.51 (1), p.689-689, Article 689</ispartof><rights>The Author(s), under exclusive licence to Springer Nature B.V. 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to Springer Nature B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c256t-192dfc41d8e56d24113e1cafa55d89fd43ca2a24c59d56c8c81417a5397d74333</cites><orcidid>0000-0002-4297-8061 ; 0000-0002-2923-1027 ; 0000-0003-0648-4694 ; 0000-0001-8530-4879 ; 0000-0001-6368-2596</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11033-024-09630-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11033-024-09630-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27926,27927,41490,42559,51321</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38796651$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aboulela, Aliaa</creatorcontrib><creatorcontrib>Taha, Mona</creatorcontrib><creatorcontrib>Ghazal, Abeer</creatorcontrib><creatorcontrib>Baess, Ayman</creatorcontrib><creatorcontrib>Elsheredy, Amel</creatorcontrib><title>Alternations in miR-155 and miR-200 serum levels can serve as biomarkers for COVID-19 in the post-mass vaccination era</title><title>Molecular biology reports</title><addtitle>Mol Biol Rep</addtitle><addtitle>Mol Biol Rep</addtitle><description>Background
Mass vaccination and natural immunity reduced the severity of COVID-19 cases. SARS-CoV-2 ongoing genome variations imply the use of confirmatory serologic biomarkers besides PCR for reliable diagnosis. MicroRNA molecules are intrinsic components of the innate immune system. The expression of miR155-5p and miR200c-3p was previously correlated with SARS-CoV-2 pathogenesis. This case-control study was conducted during the third peak of the COVID-19 pandemic in Egypt and aimed to calculate the accuracy of miR155-5p and miR200c-3p as biomarkers for COVID-19.
Methods and results
Thirty out of 400 COVID-19 patients at a main University hospital in Alexandria were included in the study along with 20 age-matched healthy controls. Plasma samples were collected for total and differential CBC. Relative quantitation of miR155-5p and miR200c-3p expression from WBCs was done by RT-qPCR. The expression of miR155-5p and miR200c-3p was positively correlated and was significantly downregulated in COVID-19 patients compared to the healthy control group (p ˂ 0.005). Both miR155-5p and miR200c-3p were of 76% and 74% accuracy as diagnostic biomarkers of COVID-19, respectively. Regarding the differentiation between mild and moderate cases, their accuracy was 80% and 70%, respectively.
Conclusions
miR155-5p and miR200c-3p expression can be used to confirm the diagnosis of COVID-19 and discriminate between mild and moderate cases, with a moderate degree of accuracy.</description><subject>Accuracy</subject><subject>Adult</subject><subject>Animal Anatomy</subject><subject>Animal Biochemistry</subject><subject>Biomarkers</subject><subject>Biomarkers - blood</subject><subject>Biomedical and Life Sciences</subject><subject>Case-Control Studies</subject><subject>COVID-19</subject><subject>COVID-19 - blood</subject><subject>COVID-19 - diagnosis</subject><subject>COVID-19 vaccines</subject><subject>Diagnosis</subject><subject>Egypt - epidemiology</subject><subject>Female</subject><subject>Genomes</subject><subject>Histology</subject><subject>Humans</subject><subject>Immune system</subject><subject>Innate immunity</subject><subject>Life Sciences</subject><subject>Male</subject><subject>MicroRNAs - blood</subject><subject>MicroRNAs - genetics</subject><subject>Middle Aged</subject><subject>miRNA</subject><subject>Morphology</subject><subject>Original Article</subject><subject>SARS-CoV-2 - genetics</subject><subject>Serum levels</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccination</subject><issn>0301-4851</issn><issn>1573-4978</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1LHTEUhoO06PXjD3QhgW66SZuTz5mlXNsqCIKo2xCTTDt2Pq45Mxf89811bAsuukpInvMcznkJ-QD8M3BuvyAAl5JxoRivjeRM7JEVaCuZqm31jqy45MBUpeGAHCI-cs4VWL1PDmRla2M0rMj2rJtSHvzUjgPSdqB9e8NAa-qH-HIXnFNMee5pl7apQxr8sHvYJuqRPrRj7_OvlJE2Y6br6_vLcwb1TjT9THQz4sR6j0i3PoR2aUNT9sfkfeM7TCev5xG5-_b1dn3Brq6_X67PrlgQ2kzFJGITFMQqaROFApAJgm-81rGqm6hk8MILFXQdtQlVqKBM6LWsbbRKSnlEPi3eTR6f5oST61sMqev8kMYZneSGW2WVgIJ-fIM-jnPZTLdQBTPSFEosVMgjYk6N2-S2rODZAXe7VNySiiupuJdUnChFp6_q-aFP8W_JnxgKIBcAy9fwI-V_vf-j_Q2kZ5Tv</recordid><startdate>20241201</startdate><enddate>20241201</enddate><creator>Aboulela, Aliaa</creator><creator>Taha, Mona</creator><creator>Ghazal, Abeer</creator><creator>Baess, Ayman</creator><creator>Elsheredy, Amel</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4297-8061</orcidid><orcidid>https://orcid.org/0000-0002-2923-1027</orcidid><orcidid>https://orcid.org/0000-0003-0648-4694</orcidid><orcidid>https://orcid.org/0000-0001-8530-4879</orcidid><orcidid>https://orcid.org/0000-0001-6368-2596</orcidid></search><sort><creationdate>20241201</creationdate><title>Alternations in miR-155 and miR-200 serum levels can serve as biomarkers for COVID-19 in the post-mass vaccination era</title><author>Aboulela, Aliaa ; Taha, Mona ; Ghazal, Abeer ; Baess, Ayman ; Elsheredy, Amel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c256t-192dfc41d8e56d24113e1cafa55d89fd43ca2a24c59d56c8c81417a5397d74333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Accuracy</topic><topic>Adult</topic><topic>Animal Anatomy</topic><topic>Animal Biochemistry</topic><topic>Biomarkers</topic><topic>Biomarkers - blood</topic><topic>Biomedical and Life Sciences</topic><topic>Case-Control Studies</topic><topic>COVID-19</topic><topic>COVID-19 - blood</topic><topic>COVID-19 - diagnosis</topic><topic>COVID-19 vaccines</topic><topic>Diagnosis</topic><topic>Egypt - epidemiology</topic><topic>Female</topic><topic>Genomes</topic><topic>Histology</topic><topic>Humans</topic><topic>Immune system</topic><topic>Innate immunity</topic><topic>Life Sciences</topic><topic>Male</topic><topic>MicroRNAs - blood</topic><topic>MicroRNAs - genetics</topic><topic>Middle Aged</topic><topic>miRNA</topic><topic>Morphology</topic><topic>Original Article</topic><topic>SARS-CoV-2 - genetics</topic><topic>Serum levels</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aboulela, Aliaa</creatorcontrib><creatorcontrib>Taha, Mona</creatorcontrib><creatorcontrib>Ghazal, Abeer</creatorcontrib><creatorcontrib>Baess, Ayman</creatorcontrib><creatorcontrib>Elsheredy, Amel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular biology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aboulela, Aliaa</au><au>Taha, Mona</au><au>Ghazal, Abeer</au><au>Baess, Ayman</au><au>Elsheredy, Amel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alternations in miR-155 and miR-200 serum levels can serve as biomarkers for COVID-19 in the post-mass vaccination era</atitle><jtitle>Molecular biology reports</jtitle><stitle>Mol Biol Rep</stitle><addtitle>Mol Biol Rep</addtitle><date>2024-12-01</date><risdate>2024</risdate><volume>51</volume><issue>1</issue><spage>689</spage><epage>689</epage><pages>689-689</pages><artnum>689</artnum><issn>0301-4851</issn><eissn>1573-4978</eissn><abstract>Background
Mass vaccination and natural immunity reduced the severity of COVID-19 cases. SARS-CoV-2 ongoing genome variations imply the use of confirmatory serologic biomarkers besides PCR for reliable diagnosis. MicroRNA molecules are intrinsic components of the innate immune system. The expression of miR155-5p and miR200c-3p was previously correlated with SARS-CoV-2 pathogenesis. This case-control study was conducted during the third peak of the COVID-19 pandemic in Egypt and aimed to calculate the accuracy of miR155-5p and miR200c-3p as biomarkers for COVID-19.
Methods and results
Thirty out of 400 COVID-19 patients at a main University hospital in Alexandria were included in the study along with 20 age-matched healthy controls. Plasma samples were collected for total and differential CBC. Relative quantitation of miR155-5p and miR200c-3p expression from WBCs was done by RT-qPCR. The expression of miR155-5p and miR200c-3p was positively correlated and was significantly downregulated in COVID-19 patients compared to the healthy control group (p ˂ 0.005). Both miR155-5p and miR200c-3p were of 76% and 74% accuracy as diagnostic biomarkers of COVID-19, respectively. Regarding the differentiation between mild and moderate cases, their accuracy was 80% and 70%, respectively.
Conclusions
miR155-5p and miR200c-3p expression can be used to confirm the diagnosis of COVID-19 and discriminate between mild and moderate cases, with a moderate degree of accuracy.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>38796651</pmid><doi>10.1007/s11033-024-09630-2</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-4297-8061</orcidid><orcidid>https://orcid.org/0000-0002-2923-1027</orcidid><orcidid>https://orcid.org/0000-0003-0648-4694</orcidid><orcidid>https://orcid.org/0000-0001-8530-4879</orcidid><orcidid>https://orcid.org/0000-0001-6368-2596</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-4851 |
| ispartof | Molecular biology reports, 2024-12, Vol.51 (1), p.689-689, Article 689 |
| issn | 0301-4851 1573-4978 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3060747421 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Accuracy Adult Animal Anatomy Animal Biochemistry Biomarkers Biomarkers - blood Biomedical and Life Sciences Case-Control Studies COVID-19 COVID-19 - blood COVID-19 - diagnosis COVID-19 vaccines Diagnosis Egypt - epidemiology Female Genomes Histology Humans Immune system Innate immunity Life Sciences Male MicroRNAs - blood MicroRNAs - genetics Middle Aged miRNA Morphology Original Article SARS-CoV-2 - genetics Serum levels Severe acute respiratory syndrome coronavirus 2 Vaccination |
| title | Alternations in miR-155 and miR-200 serum levels can serve as biomarkers for COVID-19 in the post-mass vaccination era |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T08%3A00%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alternations%20in%20miR-155%20and%20miR-200%20serum%20levels%20can%20serve%20as%20biomarkers%20for%20COVID-19%20in%20the%20post-mass%20vaccination%20era&rft.jtitle=Molecular%20biology%20reports&rft.au=Aboulela,%20Aliaa&rft.date=2024-12-01&rft.volume=51&rft.issue=1&rft.spage=689&rft.epage=689&rft.pages=689-689&rft.artnum=689&rft.issn=0301-4851&rft.eissn=1573-4978&rft_id=info:doi/10.1007/s11033-024-09630-2&rft_dat=%3Cproquest_cross%3E3060747421%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3060074636&rft_id=info:pmid/38796651&rfr_iscdi=true |